Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - November 2011

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Naproxen 500mg and esomeprazole 20mg (Vimovo®) has been rejected for use in the symptomatic treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. The economic analysis submitted was not sufficiently robust to gain approval.

Golimumab (Simponi®) has been accepted for restricted use in combination with methotrexate, for the treatment of moderate to severe, active rheumatoid arthritis in adult patients where the response to other treatments has been inadequate. The restriction applies to use of the product in accordance with the British Society for Rheumatology guidance at a maximum dose of 50mg.

Adalimumab (Humira®) has been accepted for restricted use in combination with methotrexate for the treatment of active polyarticular juvenile idiopathic arthritis, in children and adolescents aged 4 to 17 years. The restriction applies to use within specialist rheumatology services.

Abatacept (Orencia®) has been accepted for restricted use in combination with methotrexate, abatacept is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in paediatric patients 6 years of age and older. The restriction applies to use within specialist rheumatology services.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - November 2011' on Email Share 'SMC Update - November 2011' on Delicious Share 'SMC Update - November 2011' on Digg Share 'SMC Update - November 2011' on Facebook Share 'SMC Update - November 2011' on Google+ Share 'SMC Update - November 2011' on reddit Share 'SMC Update - November 2011' on StumbleUpon Share 'SMC Update - November 2011' on Twitter

atomic-wealth

3 Comments to “SMC Update - November 2011”

  1. […] ejemplo de Dinamarca respecto a racionalidad en financiación pública de medicamentos toca poner otro ejemplo, el de […]

    Pingback by Los Fármacos Malos Los Pagará Su Fabricante — August 29, 2013 #
    Reply

  2. [...] ejemplo de Dinamarca respecto a racionalidad en financiación pública de medicamentos toca poner otro ejemplo, el de Escocia: “Naproxen 500mg and esomeprazole 20mg (Vimovo®) has been rejected [...]

    Pingback by Los Fármacos Malos Los Pagará Su Fabricante | Miguel Jara — November 25, 2011 #
    Reply

  3. [...] Más información [...]

    Pingback by La Financiación “ciega” De Los Medicamentos. El Caso Vimomo | Nogracias.eu — November 16, 2011 #
    Reply

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,512 spam comments.

atomic-wealth
fond-illness
summer